Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
about
Ribavirin plus interferon versus interferon for chronic hepatitis CComparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.Rapid and early virological response to chronic hepatitis C treatment with IFN 2b or PEG-IFN 2b plus ribavirin in HIV/HCV co-infected patientsOccult infection with hepatitis C virus: friend or foe?Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C.Occult hepatitis C: how convincing are the current data?Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.The hepatic flaviviridae: summary.Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelingHepatitis C virus infection: early diagnosis and identification of response to antiviral therapy.Ribavirin monotherapy increases sustained response rate in relapsers of end treatment virologic responders.Clinical relevance of viral dynamics and genotypes in hepatitis B virus.Apoptosis in hepatitis C virus infection.Apoptosis in hepatitis C.Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patientsPharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infectionReview article: predicting response in hepatitis C virus therapy.Chronic hepatitis C virus infection: genotyping and its clinical role.Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy.Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.Determining Ribavirin's mechanism of action against Lassa virus infection.Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs.Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatment.Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alfa therapy.Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group.Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation.Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response.Clearance kinetics of hepatitis C virus under different antiviral therapies.Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C.Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients--results of a randomized, prospective, pilot study.Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.First phase hepatitis c viral kinetics in previous nonresponders patients.High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C.
P2860
Q24240879-99D79152-AB56-4A62-BE96-79063F4FF6E7Q27473034-29FD45B1-101E-461B-93A6-2728622E2BA2Q27481046-46A3B5DD-32C9-4212-B7A7-AC9A654FB2C8Q30416187-BFC477C2-5580-4785-8055-C67F507F2B2FQ33338255-E9DA1E3A-F82D-4BBD-AB62-F9731107B31AQ33395436-5E8359D9-600C-4327-9D88-B9505D49E651Q33703634-5EFB2A40-E608-4082-A4CE-BE39EE0A0A62Q33888790-1995876A-93D4-4DD8-A2F4-3803DDFDD389Q33899320-77461780-F509-4570-ABEA-36977A8C4BB2Q34569308-2E2B8DF6-A26C-4FE4-A49B-F3EA6A19D619Q35011394-FBCC4C3C-D4A3-4C10-9E75-D1FEA07698D4Q35020824-E48ECAA6-3F10-4D1F-A550-B85C381CDA2EQ35091473-EEA02174-58E8-4D1E-9A2A-2058CD21733CQ35216912-1F82A27E-1978-44C3-87F0-E0F1FD7F9263Q35621342-D8D276AF-4347-4BAB-B272-B9DCFDBA92A9Q35825285-B2B659D4-434B-4279-8FE6-E9B0EE1A6A14Q36447562-988204FB-24BF-4C8C-B420-C613BED5EA51Q36895749-94EE6E63-6EF6-45D0-B3E5-2C8E9347837DQ38166445-5A434EB6-79F4-40D8-8678-18EF25CACA58Q40547796-798856B2-80BC-431C-AE4F-35EABE173622Q40605824-C7230452-F686-4DF4-A06C-BF8DDCED8DB5Q41718140-66AA513F-29C3-45A7-BAF9-179B92284348Q41727459-5B936455-FA22-4430-8E55-69134C0BA397Q42981429-896A27AB-A1B2-4559-BF75-B8C5317168F8Q42987418-39B2FFBE-6517-4148-BC27-7246A6442326Q42992796-8E71493A-D1B6-4622-B988-ACF64EE6C3A4Q42994528-5D066815-CA3C-4E2D-AB06-750E0A7AB5CBQ42996612-5994ADE9-B7B8-412F-83B6-46B0D3DE41A1Q42998257-A422EC26-ED5B-4EF6-949D-EA1CABA5B388Q42998971-BD21488A-1F95-4380-83CA-A6EAF5176677Q43001306-638DCA65-8162-46EB-8021-3683CAE05068Q43001692-28B2E47C-43B1-4CD2-AA26-CAA5D47447A6Q43033022-3DED8575-93E0-49AC-96DE-D68C55444057Q43037216-84463AB7-5E3F-4C37-A39A-B7A6653E10EDQ43037854-10B8FAF0-B2F6-4443-9AF4-9F0A49DF79A7Q43039959-E88C34FC-A7DA-4F01-AF23-0C72814C7C5AQ43041197-8C88B344-B8ED-4E1F-85E2-F0F295B14422Q43042183-97DFB708-05E8-483B-84C5-91E07C0C3463Q43042198-01554929-B407-485A-BF55-EEA2F60B5598Q43649889-F497C58A-8F01-4E48-95E0-4681BD44BCF3
P2860
Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Hepatitis C virus dynamics in ...... rferon alfa on viral turnover.
@en
Hepatitis C virus dynamics in ...... rferon alfa on viral turnover.
@nl
type
label
Hepatitis C virus dynamics in ...... rferon alfa on viral turnover.
@en
Hepatitis C virus dynamics in ...... rferon alfa on viral turnover.
@nl
prefLabel
Hepatitis C virus dynamics in ...... rferon alfa on viral turnover.
@en
Hepatitis C virus dynamics in ...... rferon alfa on viral turnover.
@nl
P2093
P356
P1433
P1476
Hepatitis C virus dynamics in ...... rferon alfa on viral turnover.
@en
P2093
P304
P356
10.1002/HEP.510280132
P407
P577
1998-07-01T00:00:00Z